CAZ/AVI is a new antibiotic drug that is meant to be used for various indications including
cIAI and nosocomial pneumonia. To date, limited data exists on PK of CAZ/AVI in patients
undergoing peritoneal dialysis as well as on penetration of CAZ/AVI in ELF of critically ill
patients. The present study is carried out to determine target site PK of CAZ/AVI in these
two populations, in order to contribute to a more complete understanding of the drug's
penetration to its site of action.
Phase:
Phase 1
Details
Lead Sponsor:
Markus Zeitlinger
Treatments:
Avibactam Avibactam, ceftazidime drug combination Ceftazidime